The Metastatic Liver Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Metastatic Liver Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Metastatic Liver Cancer. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Metastatic Liver Cancer and features dormant and discontinued products.

GlobalData tracks 44 drugs in development for Metastatic Liver Cancer by 37 companies/universities/institutes. The top development phase for Metastatic Liver Cancer is preclinical with 20 drugs in that stage. The Metastatic Liver Cancer pipeline has 40 drugs in development by companies and four by universities/ institutes. Some of the companies in the Metastatic Liver Cancer pipeline products market are: Bristol-Myers Squibb, Sorrento Therapeutics and RemeGen.

The key targets in the Metastatic Liver Cancer pipeline products market include Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2), Cells Expressing Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5), and CD3 .

The key mechanisms of action in the Metastatic Liver Cancer pipeline product include Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Antagonist with two drugs in Phase II. The Metastatic Liver Cancer pipeline products include 13 routes of administration with the top ROA being Intravenous and 11 key molecule types in the Metastatic Liver Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.

Metastatic Liver Cancer overview

Metastatic liver cancer is a condition where cancer cells from another part of the body spread to the liver. The liver is a vital organ that performs many functions, such as filtering toxins, producing bile, and storing glycogen. Metastatic liver cancer can affect these functions and cause symptoms such as pain, jaundice, weight loss, and swelling. The most common cancers that metastasize to the liver are breast, colon, lung, and skin cancers. The diagnosis of metastatic liver cancer is based on imaging tests, blood tests, and sometimes biopsy. The treatment options depend on the type and location of the primary cancer, the number and size of the liver tumors, and the overall health of the patient. The treatments may include surgery, chemotherapy, radiation therapy, targeted therapy, or immunotherapy. The prognosis of metastatic liver cancer is generally poor, with a 5-year survival rate of 2-11%. However, some factors may improve the outlook, such as early detection, effective treatment, and good response to therapy.

For a complete picture of Metastatic Liver Cancer’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.